We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

License Agreement Turns Biotech Partners Into Rivals

Law360 (December 15, 2006, 12:00 AM EST) -- Biotech partners in a transatlantic licensing dispute are on their way to arbitration after California’s Spectrum Pharmaceuticals Inc. accused its German partner of cutting it out of a multimillion dollar sublicensing agreement.

At stake is control over satraplatin, a promising prostate-cancer drug co-developed by Spectrum and its partner, GPC Biotech AG, which allegedly cut Spectrum out of $59 million worth of sublicensing deals with another German firm, Pharmion GmbH.

According to Irvine, Calif.-based Spectrum, GPC Biotech’s deal with Pharmion violated their licensing agreement, effectively ending it....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.